What are RAS Inhibitors?
RAS (renin-angiotensin system) inhibitors are a group of medications that block different points in the renin-angiotensin-aldosterone system cascade, which regulates blood pressure, fluid balance, and cardiovascular function. These drugs include five main classes: ACE inhibitors, angiotensin receptor blockers (ARBs), mineralocorticoid receptor antagonists (MRAs), direct renin inhibitors, and beta-blockers 1, 2.
Drug Classes and Mechanisms
The RAAS can be blocked at multiple strategic points 2, 3:
- ACE Inhibitors: Block the conversion of angiotensin I to angiotensin II by inhibiting angiotensin-converting enzyme
- Angiotensin Receptor Blockers (ARBs): Block angiotensin II type 1 receptors (AT1R), preventing angiotensin II from exerting its effects 4
- Mineralocorticoid Receptor Antagonists (MRAs): Block aldosterone receptors (e.g., spironolactone, eplerenone) 1
- Direct Renin Inhibitors: Block the first and rate-limiting step by inhibiting renin's cleavage of angiotensinogen to angiotensin I (e.g., aliskiren) 2, 5
- Beta-blockers: Inhibit renin secretion, providing indirect RAAS blockade 6
Clinical Applications
These medications are cornerstone therapies for multiple cardiovascular and renal conditions 1, 3:
- Hypertension management
- Heart failure with reduced ejection fraction (HFrEF)
- Post-myocardial infarction
- Diabetic nephropathy and proteinuria
- Chronic kidney disease
- Prevention of cardiovascular events in high-risk patients
Key Clinical Considerations
Guideline-Directed Therapy
Despite proven mortality benefits, only 22-30% of eligible patients achieve guideline-recommended target doses of RAAS inhibitors 1. Hyperkalaemia is the reason for non-use or dose reduction in 8.5% of ACE inhibitor/ARB patients and 35.1% of MRA patients 1.
Hyperkalaemia Management
Hyperkalaemia is the primary barrier to optimal RAAS inhibitor dosing, occurring in up to 50% of unselected real-world populations receiving these medications 1. This risk necessitates regular potassium and creatinine monitoring, though such monitoring is frequently inadequate in clinical practice 1.
Combination Therapy Caution
Triple RAAS inhibition (ACE inhibitor + ARB + beta-blocker) may produce adverse effects and should be approached cautiously 6. While dual blockade with ACE inhibitor plus ARB can provide enhanced organ protection 3, complete blockade of the RAAS has shown potential harm in animal studies and post-hoc analyses 6.
Common Pitfalls
- Premature discontinuation: Patients often have RAAS inhibitors stopped after a single elevated potassium reading, offsetting survival benefits 1
- Inadequate monitoring: Potassium levels are frequently under-monitored, particularly in high-risk patients 1
- Suboptimal dosing: Reaching <50% of recommended ACE inhibitor/ARB doses is associated with increased risk of death and heart failure hospitalization 1